tirzepatide phase 2 obesity for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Shifting the Scales: Tirzepatide's Breakthrough

doi: 10.3389/fnut.2026.1809416 Received 11 February 2026 Revised 24 April 2026 Accepted 11 May 2026 Published 02 June 2026 Volume 13 - 2026 Edited by Ivana arac, University of Belgrade, Serbia Reviewed by Dbora Luana Ribeiro Pessoa, Federal University of Maranho, Brazil Jiaqi Liu, University of Texas Health Science Center at Houston, United States Updates Copyright 2026 Song, Fang, Li, Fu, He, Gao, Tian and Gao

Ma Q, Liao X, Shao C, et al

The MHRA is the medicines regulator for the whole of the United Kingdom, including Northern Ireland, following the implementation of the Windsor Framework for medicines (from 1 January 2025)

Gibt es bekannte Nebenwirkungen bei der Einnahme

After first use, the pen can be stored for up to 6 weeks either below 30C or in a refrigerator (2C to 8C)